MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase ½ clinical trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.…
MeiraGTx Announces Oral Presentation at ObesityWeek 2026
MeiraGTx Holdings (NASDAQ: MGTX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 386 employees.
The shares were at 7.980 USD on 20 November 2026, down 5.8% over 52 weeks. Its 52-week range is 6.620 USD to 15.35 USD: the price is 48.0% below the high and 20.5% above the low.
At a market capitalisation of 779.89M USD, it trades at 9.2 times trailing earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a discount of 72% for MGTX.
MeiraGTx Holdings reports an operating margin of 44.8%.
It holds more cash than debt, a net cash position of 50.80M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 8 analysts cover the stock, with an average rating of Buy; their mean price target of 27.75 USD is 247.7% above the current price. The next earnings report is expected on 25 March 2027.